

Ref. No: 006010422  
From: Commercial  
Date: 01/04/22  
Subject: Melanoma

## REQUEST

The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:

- Bevacizumab (Avastin)
- Dacarbazine (DTIC)
- Trametinib (Mekinist)
- Dabrafenib (Tafinlar)
- Ipilimumab (Yervoy)
- Vemurafenib (Zelboraf)
- Nivolumab (Opdivo)
- Nivolumab + Ipilimumab (Opdivo + Yervoy)
- Pembrolizumab (Keytruda)
- Vemurafenib + cobimetinib (Zelboraf + Cotellic)
- Dabrafenib + Trametinib (Tafinlar + Mekinist)
- Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients

- Other active systemic anti-cancer therapy [please state]
- Palliative care only

Q2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:

- Ipilimumab
- Ipilimumab AND Nivolumab
- Nivolumab
- Pembrolizumab
- Dabrafenib AND Trametinib
- Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
- Other active systemic anti-cancer therapy
- Palliative care only

## RESPONSE

Q1

The Trust does not record specific drug names prescribed to patients.

The number of melanoma patients who received palliative care only during the 3 month timeframe 01/12/2021 – 28/02/2022 was **0**

Q2

St Helens & Knowsley Teaching Hospitals Trust does not hold this information. Please re-direct your request to The Clatterbridge Cancer Centre NHS Foundation Trust

Contact Details are as follows:

The Clatterbridge Cancer Centre NHS Foundation Trust

Clatterbridge Road

Bebington

Wirral

CH63 4JY

Tel 0151 556 5000

The number of metastatic melanoma patients who received palliative care only during the 3 month timeframe 01/12/2021 – 28/02/2022 was **0**